PSORIASIS, ECZEMA, DERMATITIS
Physiopathology:
Although Psoriasis, Eczema & Dermatitis are classified as different diseases, all histological sections of PE&D lesions show a common picture: excessive & uncontrolled growth of dermal cells, very high numbers of cytokine-secreting immunological cells, widespread presence of inflammatory cells, & secondary microbial contamination.
Ideal Treatment Approach:
As autoimmune dysfunctions cannot presently be treated, mechanically removing contaminants and undesirable particles from the lesion so as to provide a clean and hydrated environment favorable to natural normalization of cell growth and lesion healing is the only symptomatic treatment to ease symptoms of the disease.
50mL Class IIa Medical Device for the treatment of Lesions of Psoriasis, Eczema & Dermatitis (Official Indication)
Currently Available Treatments:
Topical cell growth regulators: none
All the currently available treatments such as: anti-inflammatory drugs, corticosteroids, Vitamin A & D analogues, immune-modulators, immune-suppressants, as well as specific inhibitors of T-cells or leukocytes, interleukin inhibitors, TNF-alpha blockers, and anti-mitotic drugs, are directed to block only partially the cause, whereas their systemic presence induces serious side effects.
VITROBIO’s Completely NEW Therapeutic Approach:
A clean, hydrated environment for fast lesion healing.
In 1994, Vitrobio discovered & patented a hypertonic viscous liquid solution, derived from polyols, 18 times more osmotically active than sea water yet NON-IRRITANT, capable of generating an instant flow of hypotonic liquid when applied on a live biological, semi-permeable, membrane (International patent 1997: PCT/FR99/01340). Applying this solution on lesions cleans the injury of all the contaminants and other undesirable particles including those stimulating uncontrolled cell growth & inflammation, and impurities present on the surface of lesions within a few minutes. The filmogen capacity of this solution was enhanced to offer a longer acting filmogen bandage (2013 patent: PCT/EP2013/061835).
Product Presentation: 50mL Tube containing a viscous, brownish solution for topical application.
Posology: Dose depends on lesion size; 2-3 applications per day in the beginning, then once a day until complete recovery.
Regulatory Status: Due to totally mechanical & topical filmogen activity without any pharmacological, biological, metabolic or immunological interaction with the cellular structure: Class IIa Medical Device in Europe.
Contraindications: Cannot be applied on smooth, non-porous skin; requires light scraping if the skin is keratinized.
Clinical Efficacy:
Compared to OTC or Rx treatments, VB-DERM significantly reduced Erythema & Pruritus, Oedema, Oozing, Dryness, Itching, and improves overall Quality of life right from the 2nd week of treatment, demonstrating high efficacy in treating all symptoms associated with PED skin diseases
